| Objective: Bone marrow-derived mesenchymal stem cells(BMSCs)have been shown to facilitate spinal cord injury(SCI)repair in animal models.However,BMSCs transplantation has not yet been widely used clinically.The safety and efficacy of BMSCs in patients with SCI remains controversial.Therefore,we pooled the use of autologous BMSCs in patients with SCI to assess the corresponding safety.Methods: We conducted systematic searches in Pubmed,Web of Science,Cochrane Library,CNKI and Wanfang databases for the use of autologous BMSCs in patients with SCI in published articles from 2010 to 2022.Results:A network meta-analysis revealed that the American Spinal Cord Injury Association(ASIA)motor and ASIA sensory scores,improvement in ASIA grade,improvement in bladder function,improvement in sensory-evoked potential SSEP,and incidence of adverse effects.The results of the meta-analysis showed that compared with control,autologous BMSCs transplantation improved ASIA sensory scores(mean difference(MD),8.41;95% confidence interval(CI),5.67-11.14),ASIA motor score(MD,10.34;95% CI,8.33-12.35),improvement in ASIA impairment scale grade(relative risk(RR),4.50;95% CI,2.04-9.91),improved bladder function(RR,1.93;95%CI,1.06-3.50),somatosensory evoked potential(SSEP)improvement(RR,2.96;95% CI,1.43-6.12)and incidence of adverse effects(RR,1.27;95% CI,0.58-2.77).Conclusion: Autologous BMSCs transplantation can improve the ASIA sensory score,ASIA motor function score,ASIA injury scale grading,bladder function recovery,and SSEP recovery in SCI patients without serious adverse reactions.Therefore,autologous mesenchymal stem cell transplantation is safe and effective for the recovery of SCI patients. |
